Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Total Debt (2022 - 2025)

Historic Total Debt for Immunocore Holdings (IMCR) over the last 4 years, with Q3 2025 value amounting to $392.6 million.

  • Immunocore Holdings' Total Debt rose 53.75% to $392.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $392.6 million, marking a year-over-year increase of 53.75%. This contributed to the annual value of $391.0 million for FY2024, which is 71442.38% up from last year.
  • According to the latest figures from Q3 2025, Immunocore Holdings' Total Debt is $392.6 million, which was up 53.75% from $392.1 million recorded in Q2 2025.
  • Immunocore Holdings' 5-year Total Debt high stood at $438.1 million for Q2 2024, and its period low was $47.8 million during Q4 2022.
  • Its 4-year average for Total Debt is $325.5 million, with a median of $391.5 million in 2025.
  • In the last 5 years, Immunocore Holdings' Total Debt skyrocketed by 71442.38% in 2024 and then tumbled by 1051.64% in 2025.
  • Immunocore Holdings' Total Debt (Quarter) stood at $47.8 million in 2022, then increased by 0.43% to $48.0 million in 2023, then soared by 714.42% to $391.0 million in 2024, then grew by 0.4% to $392.6 million in 2025.
  • Its Total Debt stands at $392.6 million for Q3 2025, versus $392.1 million for Q2 2025 and $391.5 million for Q1 2025.